Digestive and Liver Disease
Volume 42, Issue 8 , Pages 578-584 , August 2010

Total and covalently closed circular DNA detection in liver tissue of long-term survivors transplanted for HBV-related cirrhosis

  • Ilaria Lenci

      Affiliations

    • Hepatology Unit, Department of Internal Medicine, Tor Vergata University, Via Montpellier 1-00133 Rome, Italy
    • Corresponding Author InformationCorresponding author at: Chair of Gastroenterology, Hepatology Unit, Department of Internal Medicine, Tor Vergata University, Via Montpellier 1-00133 Rome, Italy. Tel.: +39 06 72596803.
    • ,
  • Fabio Marcuccilli

      Affiliations

    • Laboratory of Molecular Virology, Tor Vergata Medical School, Rome, Italy
    • ,
  • Giuseppe Tisone

      Affiliations

    • Liver Transplant Unit, Tor Vergata Medical School, Rome, Italy
    • ,
  • Daniele Di Paolo

      Affiliations

    • Hepatology Unit, Department of Internal Medicine, Tor Vergata University, Via Montpellier 1-00133 Rome, Italy
    • ,
  • Laura Tariciotti

      Affiliations

    • Liver Transplant Unit, Tor Vergata Medical School, Rome, Italy
    • ,
  • Marco Ciotti

      Affiliations

    • Laboratory of Molecular Virology, Tor Vergata Medical School, Rome, Italy
    • ,
  • Tania Guenci

      Affiliations

    • Laboratory of Molecular Virology, Tor Vergata Medical School, Rome, Italy
    • ,
  • Carlo Federico Perno

      Affiliations

    • Laboratory of Molecular Virology, Tor Vergata Medical School, Rome, Italy
    • ,
  • Mario Angelico

      Affiliations

    • Hepatology Unit, Department of Internal Medicine, Tor Vergata University, Via Montpellier 1-00133 Rome, Italy

Received 15 September 2009 ,Accepted 6 December 2009.

References 

  1. Todo S, Demetris AJ, Van Thiel D, et al. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology. 1991;13:619–626
  2. O’Grady JG, Smith HM, Davies SE, et al. Hepatitis B reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol. 1992;14:104–111
  3. Davies SE, Portman BC, O’Grady JG, et al. Hepatic histologic findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology. 1991;13:150–157
  4. Dumortier J, Chevallier P, Scoazec JY, et al. Combined lamivudine and hepatitis B immunoglobulin for the prevention of hepatitis B recurrence after liver transplantation: long-term results. Am J Transplant. 2003;3:999–1002
  5. Rosenau J, Bahr MJ, Tillmann HL, et al. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation. Possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol. 2001;34:895–902
  6. Markowitz JS, Martin P, Conrad AJ, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology. 1998;28:585–589
  7. Marzano A, Salizzoni M, Debenardi-Venon W, et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol. 2001;34:903–910
  8. Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med. 1993;16:329:1842–1847
  9. Terrault N, Wright TL. Hepatitis B virus infection and liver transplantation. Gut. 1997;40:568–571
  10. Lerut JP, Donataccio M, Cicciarelli O, et al. Liver transplantation and HBsAg-positive post-necrotic cirrhosis: adequate immunoprophylaxis and delta virus co-infection as the significant determinants of long-term prognosis. J Hepatol. 1999;30:706–714
  11. Di Paolo D, Tisone G, Piccolo P, et al. Low-dose hepatitis B immunoglobulin given “on demand” in combination with lamivudine: a highly cost-effective approach to prevent recurrent hepatitis B virus infection in the long-term follow-up after liver transplantation. Transplantation. 2004;77:1203–1208
  12. Mason WS, Cullen J, Moraleda G, et al. Lamivudine therapy of WHV-infected woodchucks. Virology. 1998;245:18–32
  13. Fourel I, Cullen JM, Saputelli J, et al. Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks. J Virol. 1994;68:8321–8330
  14. Guo JT, Zhou H, Liu C, et al. Apoptosis and regeneration of hepatocytes during recovery from transient hepadnavirus infection. J Virol. 2000;74:1495–1505
  15. Thimme R, Wieland S, Steiger C, et al. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol. 2003;77:68–76
  16. Guidotti LG, Rochford R, Chung J, et al. Viral clearance without destruction of infected cells during acute HBV infection. Science. 1999;284:825–829
  17. Perillo RP, Wright T, Rakela R, et al. A multicentre United States-Canadian trail to asses lamivudine monotherapy before and after transplantation for chronic hepatitis B. Hepatology. 2001;33:424–432
  18. Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir treatment. Gastroenterology. 2004;126:1750–1758
  19. Sung JJ, Wong ML, Bowden S, et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology. 2005;128:1890–1897
  20. Wursthorn K, Lutgehetmann M, Dandri M, et al. Pegintefron alpha-2b plus adefovir induce strong cccDNA decline anf HBsAg reduction in patients with chronic hepatitis B. Hepatology. 2006;44:675–684
  21. Wong DK, Yuen MF, Ngai VW, et al. One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels. Antivir Ther. 2006;11:909–916
  22. Hussain M, Soldevila-Pico C, Emre S, et al. Presence of intrahepatic (total and ccc) HBV-DNA is not predictive of HBV recurrence after liver transplantation (OLT). Liver Transpl. 2007;13(August):1137–1144
  23. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22(June):696–699
  24. Singh M, Dicaire A, Wakil AE, et al. Quantitation of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) in the liver of HBV-infected patients by Lightcycler™ real-time PCR. J Virol Methods. 2004;118:159–167
  25. Tong JH, Tsang RK, Lo KW, et al. Quantitative Epstein-Barr virus DNA analysis and detection of gene promoter hypermethylation in nasopharyngeal (NP) brushing samples from patients with NP carcinoma. Clin Cancer Res. 2002;August:2612–2619
  26. Roche B, Feray C, Gigou M, et al. HBV-DNA persistence 10 years after liver transplantation despite successful anti-HBs passive innumoprophylaxis. Hepatology. 2003;38:86–95
  27. Lok As , McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45:507–539
  28. Cabrerizo M, Bartolome J, Caramelo C, et al. Molecular analysis of hepatitis B virus DNA in serum and peripheral blood mononuclear cells from hepatitis B surface antigen-negative cases. Hepatology. 2000;32:116–123
  29. Kock J, Theilmann L, Galle P, et al. Hepatitis B virus nucleic acids associated with human peripheral blood mononuclear cells do not originate from replicating virus. Hepatology. 1996;23:405–413
  30. Umeda M, Marusawa H, Seno H, et al. Hepatitis B virus infection in lymphatic tissue in inactive hepatitis B carriers. J Hepatol. 2005;42:806–812
  31. Mazet-Wagner AA, Baclet MC, Loustaud-Ratti V, et al. Real-time PCR quantitation of hepatitis B virus total DNA and covalently closed circular DNA in peripheral blood mononuclear cell from hepatitis B virus-infected patients. J Virol Methods. 2006;138:70–79

PII: S1590-8658(09)00469-1

doi: 10.1016/j.dld.2009.12.003

Digestive and Liver Disease
Volume 42, Issue 8 , Pages 578-584 , August 2010

Article Tools